Clinical and biological significance of Cdk10 in hepatocellular carcinoma

Gene

Volumn 498, Issue 1, 2012, Pages 68-74

  Zhong, Xiang yu ^a   Xu, Xiao xue ^b   Yu, Jian hua ^a   Jiang, Gui xing ^a   Yu, Yang ^b   Tai, Sheng ^a   Wang, Zhi dong ^a   Cui, Yun fu ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cdk10; Clinical significance; Drug resistance; HCC; Proliferation

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; EPIRUBICIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

AGED; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; GLUCURONATES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84862784044     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.022     Document Type: Article

References (28)

1. Asghar U., Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?. J. Hepatol. 2011, (Oct 1). 10.1016/j.jhep.2011.07.031.
2. Bhutia Y.D., Hung S.W., Patel B., Lovin D., Govindarajan R. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 2011, 71:1825-1835.
3. Boni V., et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther. 2010, 9:2265-2275.
4. Brambilla R., Draetta G. Molecular cloning of PISSLRE, a novel putative member of the cdk family of protein serine/threonine kinases. Oncogene 1994, 9:3037-3041.
5. Chambers A.E., et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer 2003, 39:1165-1175.
6. Couto S.S. The pathologist's slide reveals more than meets the eye: loss of heterozygosity and cancer biology. Vet. Pathol. 2011, 48:236-244.
7. Crawford J., et al. The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. Genomics 1999, 56:90-97.
8. Edeline J., Raoul J.L., Vauleon E., Guillygomac'h A., Boudjema K., Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J. Gastroenterol. 2009, 15:713-716.
9. Evans A.A., Chen G., Ross E.A., Shen F.M., Lin W.Y., London W.T. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol. Biomarkers Prev. 2002, 11:369-376.
10. Feng H., et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis. J. Clin. Invest. 2011, 121:3159-3175.
11. Fukui R., et al. Metastases-related genes in the classification of liver and peritoneal metastasis in human gastric cancer. J. Surg. Res. 2005, 129:94-100.
12. Graña X., Claudio P.P., De Luca A., Sang N., Giordano A. PISSLRE, a human novel CDC2-related protein kinase. Oncogene 1994, 9:2097-2103.
13. Greenbaum L.E. Cell cycle regulation and hepatocarcinogenesis. Cancer Biol. Ther. 2004, 3:1200-1207.
14. Heller G., et al. CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res. 2009, 29:3939-3944.
15. Husson H., et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002, 99:282-289.
16. Iorns E., et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13:91-104.
17. Kalimutho M., et al. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. Cancer Chemother. Pharmacol. 2011, 267:1299-1312.
18. Kudo M. Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology 2010, 78(Suppl. 1):1-6.
19. Leman E.S., Magheli A., Yong K.M., Netto G., Hinz S., Getzenberg R.H. Identification of nuclear structural protein alterations associated with seminomas. J. Cell. Biochem. 2009, 108:1274-1279.
20. Li S., MacLachlan T.K., De Luca A., Claudio P.P., Condorelli G., Giordano A. The cdc-2-related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. Cancer Res. 1995, 55:3992-3995.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
22. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
23. Riou P., et al. Investigation in liver tissues and cell lines of the transcription of 13 genes mapping to the 16q24 region that are frequently deleted in hepatocellular carcinoma. Clin. Cancer Res. 2002, 8:3178-3186.
24. Santambrogio R., et al. Hepatic Resection for "BCLC Stage A" Hepatocellular Carcinoma. The Prognostic Role of Alpha-Fetoprotein. Ann. Surg. Oncol. 2011, (Jul 6). 10.1245/s10434-011-1845-6.
25. Schütte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig. Dis. 2009, 27:80-92.
26. Singhal S., et al. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol. Ther. 2003, 2:291-298.
27. Venook A.P., Papandreou C., Furuse J., de Guevara L.L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl. 4):5-13.
28. Yeh C.T., et al. Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer 2011, 11:117.